Bingham, led by partner Will Perkins, represented Shape Pharmaceuticals Inc. in a sale to TetraLogic Pharmaceuticals Corporation. Shape is a privately held biotechnology company that specializes in developing a novel tissue-targeted gel formulation HDAC inhibitor, currently used in clinical trials to treat stage IA-IIA Cutaneous T-Cell Lymphoma (CTCL). The merger adds a second clinical-stage oncology compound to Tetralogic’s portfolio of future developments and products. The Bingham team also included partner Matt Schnall, counsel Jason Rodriguez and associate Stef Lefebvre.